ישראל - עברית - Ministry of Health

syneron medical - אחר - "non-invasive treatment system of temporarily reduction of cellulite, non-invasive body contouring via temporary circumferences reduction "

ישראל - עברית - Ministry of Health

syneron medical - אחר - non-invasive treatment for body contouring via temporary cellulite and circumference reduction.

ישראל - עברית - Ministry of Health

syneron medical - אחר - non-invasive treatment system of temporarily reduction of cellulite, non-invasive body contouring via temporary circumferences reduction

ישראל - עברית - Ministry of Health

לאה ויזר - ןיעל ביבסמ רועה חופיט

ישראל - עברית - Ministry of Health

ניאופרם (ישראל) 1996 בעמ - קרם לחות לאיזור העיניים

ישראל - עברית - Ministry of Health

בירנפלד יפה - צמצום קמטים וקמטוטים

ישראל - עברית - Ministry of Health

בירנפלד יפה - שיפור מראה העור

ישראל - עברית - Ministry of Health

בירנפלד יפה - צמצום קמטים וקמטוטים

ישראל - עברית - Ministry of Health

אלפא-נטו בע"מ - רופא - עדשות תוך עיניות

ישראל - עברית - Ministry of Health

medison pharma ltd - natalizumab - תרכיז להכנת תמיסה לאינפוזיה - natalizumab 300 mg / 15 ml - natalizumab - natalizumab - tysabri is indicated as monotherapy for the treatment of patients with relapsing forms of multiple sclerosis . to delay the accumulation of physical disability and reduce the frequency of clinical exacerbations. the safety and efficacy of tysabri beyond two years are unknown. because tysabri increases the risk of progressive multifocal leukoencephalopathy (pml), an opportunistic viral infection of the brain that usually leads to death or severe disability. tysabri is generally recommended for patients who have had an inadequate response to, or are unable to tolerate, alternate multiple sclerosis therapies. safety and efficacy in patients with chronic progressive multiple sclerosis have not been studied.